2026 Q3 -tulosraportti
Vain PDF
92 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 1.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 13.2. | ||
2026 Q2 -tulosraportti 13.11.2025 | ||
Vuosittainen yhtiökokous 2025 18.8.2025 | ||
2026 Q1 -tulosraportti 13.8.2025 | ||
2025 Q4 -tulosraportti 1.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·14 t sittenhttps://www.stocktitan.net/news/BETRF/better-life-pharma-announces-appointment-of-doug-drysdale-as-lpuatnqcxuy3.html A small tip for a penny stock named betterlife pharma.. they have the patent for bromo-lsd.. a formula that is not considered "lsd" is thus exempt from the ban and can emerge as the big candidate for psychiatry and neurological treatment.. I had this before, but had to get rid of it when it became impossible to trade on the stock exchange.. I'm following it, will buy if it becomes possible!!
·26.4.(Again, continuing to write here after the image in the previous post) There are strategic differences in the choice of execution: 1. Helus Pharma (The Scalability Model): Helus has designed its protocol to fit into a normal workday. Since the effect of HLP003 wears off faster, a therapist can theoretically treat two patients in one day, or at least manage both preparation and treatment without overtime. They are also testing a model where only one certified caregiver is needed in the room, which halves personnel costs compared to Compass's model. 2. Compass Pathways (The Gold Standard Model): Compass follows a more traditional protocol with a focus on safety for severely ill (TRD) patients. They often require two people in the room (a "lead" and an "assistant") throughout the entire 6–8 hour long session. This makes the treatment significantly more expensive to carry out, but they argue that this intensive support is necessary for the specific patient group that has not responded to other help. 3. Infrastructure Requirements: Helus: Can use existing reception rooms more efficiently thanks to shorter sessions. Compass: Requires specialized rooms that are occupied a whole day for a single patient, which increases the demand on clinics' physical capacity. In summary: Helus aims to be the most "cost-effective" solution for broad depression, while Compass builds an exclusive and robust infrastructure for the most difficult cases. The "clinic-friendly" model Helus has chosen is the reason why I have chosen to invest in Helus. Yes, and then for the knockout Phase 2 study, of course. 😊- ·26.4.The treatment protocol is the largest cost factor for psychedelic therapy. The main difference between Helus and Compass lies primarily in how much staff time is required per patient, which directly affects how scalable the treatment is in healthcare. Here is a comparison of their specific protocols:
- ·26.4.(Could not write further after the image in the previous post, so the continuation follows here) Important differences to note 1. Patient Group: Compass focuses on the most difficult group (TRD), where patients have failed at least two previous treatments. Helus targets MDD more broadly, which means a potentially larger market but also more competition from traditional antidepressant drugs. 2. Efficacy vs. Time: HLP003's biggest advantage is "deuteration". By modifying the molecule, Helus has managed to shorten the psychedelic experience without losing efficacy. This is seen as a huge advantage for clinicians, as more patients can be treated per day. 3. Side Effect Profile: Both show similar side effects (headache, nausea, dizziness), but Compass COMP360 studies in Phase 2 have shown a small but noted incidence of suicidal behavior in a few patients in the TRD group, which requires careful monitoring in Phase 3. 4. Scalability: Helus HLP003 is often considered more "scalable" for healthcare because the session time requires lower personnel costs per treatment compared to Compass's longer sessions. Analysis before submission: While Compass has now received its CNPV voucher, which gives them a record-short review time of 1–2 months, the real battle lies in whether Helus's Phase 3 data (expected by the end of 2026) can demonstrate a clear advantage in treatment efficiency per hour.
- ·26.4.Here is a comparison of the clinical results and study design for Helus Pharma (HLP003) and Compass Pathways (COMP360), the two leading candidates for psilocybin-based therapy for depression.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q3 -tulosraportti
Vain PDF
92 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 t sittenhttps://www.stocktitan.net/news/BETRF/better-life-pharma-announces-appointment-of-doug-drysdale-as-lpuatnqcxuy3.html A small tip for a penny stock named betterlife pharma.. they have the patent for bromo-lsd.. a formula that is not considered "lsd" is thus exempt from the ban and can emerge as the big candidate for psychiatry and neurological treatment.. I had this before, but had to get rid of it when it became impossible to trade on the stock exchange.. I'm following it, will buy if it becomes possible!!
- ·26.4.(Again, continuing to write here after the image in the previous post) There are strategic differences in the choice of execution: 1. Helus Pharma (The Scalability Model): Helus has designed its protocol to fit into a normal workday. Since the effect of HLP003 wears off faster, a therapist can theoretically treat two patients in one day, or at least manage both preparation and treatment without overtime. They are also testing a model where only one certified caregiver is needed in the room, which halves personnel costs compared to Compass's model. 2. Compass Pathways (The Gold Standard Model): Compass follows a more traditional protocol with a focus on safety for severely ill (TRD) patients. They often require two people in the room (a "lead" and an "assistant") throughout the entire 6–8 hour long session. This makes the treatment significantly more expensive to carry out, but they argue that this intensive support is necessary for the specific patient group that has not responded to other help. 3. Infrastructure Requirements: Helus: Can use existing reception rooms more efficiently thanks to shorter sessions. Compass: Requires specialized rooms that are occupied a whole day for a single patient, which increases the demand on clinics' physical capacity. In summary: Helus aims to be the most "cost-effective" solution for broad depression, while Compass builds an exclusive and robust infrastructure for the most difficult cases. The "clinic-friendly" model Helus has chosen is the reason why I have chosen to invest in Helus. Yes, and then for the knockout Phase 2 study, of course. 😊
- ·26.4.The treatment protocol is the largest cost factor for psychedelic therapy. The main difference between Helus and Compass lies primarily in how much staff time is required per patient, which directly affects how scalable the treatment is in healthcare. Here is a comparison of their specific protocols:
- ·26.4.(Could not write further after the image in the previous post, so the continuation follows here) Important differences to note 1. Patient Group: Compass focuses on the most difficult group (TRD), where patients have failed at least two previous treatments. Helus targets MDD more broadly, which means a potentially larger market but also more competition from traditional antidepressant drugs. 2. Efficacy vs. Time: HLP003's biggest advantage is "deuteration". By modifying the molecule, Helus has managed to shorten the psychedelic experience without losing efficacy. This is seen as a huge advantage for clinicians, as more patients can be treated per day. 3. Side Effect Profile: Both show similar side effects (headache, nausea, dizziness), but Compass COMP360 studies in Phase 2 have shown a small but noted incidence of suicidal behavior in a few patients in the TRD group, which requires careful monitoring in Phase 3. 4. Scalability: Helus HLP003 is often considered more "scalable" for healthcare because the session time requires lower personnel costs per treatment compared to Compass's longer sessions. Analysis before submission: While Compass has now received its CNPV voucher, which gives them a record-short review time of 1–2 months, the real battle lies in whether Helus's Phase 3 data (expected by the end of 2026) can demonstrate a clear advantage in treatment efficiency per hour.
- ·26.4.Here is a comparison of the clinical results and study design for Helus Pharma (HLP003) and Compass Pathways (COMP360), the two leading candidates for psilocybin-based therapy for depression.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 1.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 13.2. | ||
2026 Q2 -tulosraportti 13.11.2025 | ||
Vuosittainen yhtiökokous 2025 18.8.2025 | ||
2026 Q1 -tulosraportti 13.8.2025 | ||
2025 Q4 -tulosraportti 1.7.2025 |
2026 Q3 -tulosraportti
Vain PDF
92 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 -tulosraportti 1.7. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 -tulosraportti 13.2. | ||
2026 Q2 -tulosraportti 13.11.2025 | ||
Vuosittainen yhtiökokous 2025 18.8.2025 | ||
2026 Q1 -tulosraportti 13.8.2025 | ||
2025 Q4 -tulosraportti 1.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·14 t sittenhttps://www.stocktitan.net/news/BETRF/better-life-pharma-announces-appointment-of-doug-drysdale-as-lpuatnqcxuy3.html A small tip for a penny stock named betterlife pharma.. they have the patent for bromo-lsd.. a formula that is not considered "lsd" is thus exempt from the ban and can emerge as the big candidate for psychiatry and neurological treatment.. I had this before, but had to get rid of it when it became impossible to trade on the stock exchange.. I'm following it, will buy if it becomes possible!!
- ·26.4.(Again, continuing to write here after the image in the previous post) There are strategic differences in the choice of execution: 1. Helus Pharma (The Scalability Model): Helus has designed its protocol to fit into a normal workday. Since the effect of HLP003 wears off faster, a therapist can theoretically treat two patients in one day, or at least manage both preparation and treatment without overtime. They are also testing a model where only one certified caregiver is needed in the room, which halves personnel costs compared to Compass's model. 2. Compass Pathways (The Gold Standard Model): Compass follows a more traditional protocol with a focus on safety for severely ill (TRD) patients. They often require two people in the room (a "lead" and an "assistant") throughout the entire 6–8 hour long session. This makes the treatment significantly more expensive to carry out, but they argue that this intensive support is necessary for the specific patient group that has not responded to other help. 3. Infrastructure Requirements: Helus: Can use existing reception rooms more efficiently thanks to shorter sessions. Compass: Requires specialized rooms that are occupied a whole day for a single patient, which increases the demand on clinics' physical capacity. In summary: Helus aims to be the most "cost-effective" solution for broad depression, while Compass builds an exclusive and robust infrastructure for the most difficult cases. The "clinic-friendly" model Helus has chosen is the reason why I have chosen to invest in Helus. Yes, and then for the knockout Phase 2 study, of course. 😊
- ·26.4.The treatment protocol is the largest cost factor for psychedelic therapy. The main difference between Helus and Compass lies primarily in how much staff time is required per patient, which directly affects how scalable the treatment is in healthcare. Here is a comparison of their specific protocols:
- ·26.4.(Could not write further after the image in the previous post, so the continuation follows here) Important differences to note 1. Patient Group: Compass focuses on the most difficult group (TRD), where patients have failed at least two previous treatments. Helus targets MDD more broadly, which means a potentially larger market but also more competition from traditional antidepressant drugs. 2. Efficacy vs. Time: HLP003's biggest advantage is "deuteration". By modifying the molecule, Helus has managed to shorten the psychedelic experience without losing efficacy. This is seen as a huge advantage for clinicians, as more patients can be treated per day. 3. Side Effect Profile: Both show similar side effects (headache, nausea, dizziness), but Compass COMP360 studies in Phase 2 have shown a small but noted incidence of suicidal behavior in a few patients in the TRD group, which requires careful monitoring in Phase 3. 4. Scalability: Helus HLP003 is often considered more "scalable" for healthcare because the session time requires lower personnel costs per treatment compared to Compass's longer sessions. Analysis before submission: While Compass has now received its CNPV voucher, which gives them a record-short review time of 1–2 months, the real battle lies in whether Helus's Phase 3 data (expected by the end of 2026) can demonstrate a clear advantage in treatment efficiency per hour.
- ·26.4.Here is a comparison of the clinical results and study design for Helus Pharma (HLP003) and Compass Pathways (COMP360), the two leading candidates for psilocybin-based therapy for depression.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt